Abstract:Background: Abnormal bone metabolism and renal anemia seriously affect the prognosis of patients with chronic kidney disease (CKD). Existing studies have mostly addressed the pathogenesis and treatment of bone metabolism abnormality and anemia in patients with CKD, but few have evaluated their mutual connection. Administration of exogenous erythropoietin to CKD patients with anemia used to be the mainstay of therapeutic approaches; however, with the availability of hypoxia-inducible factor (HIF) stabilizers such as roxadustat, more therapeutic choices for renal anemia are expected in the future. However, the effects posed by the hypoxic environment on both CKD complications remain incompletely understood. Aim: To summarize the relationship between renal anemia and abnormal bone metabolism, and to discuss the influence of hypoxia on bone metabolism. Methods: CNKI and PubMed searches were performed using the key words "chronic kidney disease," "abnormal bone metabolism," "anemia," "hypoxia," and "HIF" to identify relevant articles published in multiple languages and fields. Reference lists from identified articles were reviewed to extract additional pertinent articles. Then we retrieved the Abstract and Introduction and searched the results from the literature, classified the extracted information, and summarized important information. Finally, we made our own conclusions. Results: There is a bidirectional relationship between renal anemia and abnormal bone metabolism. Abnormal vitamin D metabolism and hyperparathyroidism can affect bone metabolism, blood cell production, and survival rates through multiple pathways. Anemia will further attenuate the normal bone growth. The hypoxic environment regulates bone morphogenetic protein, vascular endothelial growth factor, and neuropilin-1, and affects osteoblast/osteoclast maturation and differentiation through bone metabolic changes. Hypoxia preconditioning of mesenchymal stem cells (MSCs) can enhance their paracrine effects and promote fracture healing. Concurrently, hypoxia reduces the inhibitory effect on osteocyte differentiation by inhibiting the expression of fibroblast growth factor 23. Hypoxia potentially improves bone metabolism, but it still carries potential risks. The optimal concentration and duration of hypoxia remain unclear. Conclusion: There is a bidirectional relationship between renal anemia and abnormal bone metabolism. Hypoxia may improve bone metabolism but the concentration and duration of hypoxia remain unclear and need further study.

The relationships among gut microbiota, hypoxia-inducible factor and anaemia with chronic kidney disease

The Interaction of Gut Microflora with Liver and Kidney Disease

Gut Microbiota in Patients Receiving Dialysis: A Review

Recent advances of gut microbiota in chronic kidney disease patients

Gut Dysbiosis and Its Role in the Anemia of Chronic Kidney Disease

The Role of the Gut Microbiota in Complications among Hemodialysis Patients

Gut microbiota regulates oxidative stress and inflammation: a double-edged sword in renal fibrosis

Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies

Gut microbial metabolites SCFAs and chronic kidney disease

Gut Microbiota Correlates With Clinical Responsiveness to Erythropoietin in Hemodialysis Patients With Anemia

Microbiome–metabolome reveals the contribution of gut–kidney axis on kidney disease

The Immunomodulatory Effect of the Gut Microbiota in Kidney Disease

Effects of hypoxia on bone metabolism and anemia in patients with chronic kidney disease

Stabilizing Hypoxia-Inducible Factor to Manage Anemia in Chronic Kidney Disease: From Basic Theory to Clinical Study

The gut microbiota and its relationship with chronic kidney disease

The gut microbiome tango in the progression of chronic kidney disease and potential therapeutic strategies

Hypoxia, HIF, and Associated Signaling Networks in Chronic Kidney Disease

Oral and intravenous iron treatment alter the gut microbiome differentially in dialysis patients

Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a document by the European Renal Best Practice board of the European Renal Association

Association between gut dysbiosis and chronic kidney disease: a narrative review of the literature